With most sub-Saharan African countries facing problems of raising revenues for financing the delivery of an essential package of health services, there has been growing interest in social health insurance (SHI) as shown by efforts in Ghana, Kenya, Lesotho, Nigeria, Rwanda, South Africa,...

The administration of (biologically-derived) drugs for various disease conditions involves consumption of resources that constitutes a direct monetary cost to healthcare payers and providers. An often ignored cost relates to a mismatch between patients' preferences and the mode of drug...

Medicines are integral of any healthcare system, and limited access to medicines undermines health systems' objectives of equity, efficiency and health development. In African countries, where it is estimated that 50-60% of the populace lack "access" to essential medicines, health problems...

The administration of (biologically-derived) drugs for various disease conditions involves consumption of resources that constitutes a direct monetary cost to healthcare payers and providers. An often ignored cost relates to a mismatch between patients’ preferences and the mode of drug...

Public health-sectors of most low- and middle-income countries (LMICs) run a central medical stores (CMS) supply chain model in their efforts to assure commodity security, defined as uninterrupted supply of health commodities whenever and wherever these commodities are needed. Concerns raised...

Consumption of quality-assured medicines is expected to maintain or improve population health. Yet in a number of situations, what is realized is lower health benefits or magnified safety-risks. Recognizing the public-health implications of safety-risks or medication-related harm, and that harm...

Health planners and program managers charged with the task of building or at least maintaining the health of populations within communities, districts, regions or countries have to find ways of assuring a steady (predictable) supply of health commodities for the production of needed healthcare...

Appraising pharmaceutical products at different time points of their lifecycle open ups the possibility of reversals in estimates of economic value. A product that erstwhile was rated “not cost-effective” could later on become 'cost-effective'. This paper investigates, within a single...